Total Payments
$121,941
2024 Payments
$37,861
Companies
15
Transactions
144
Medicare Patients
2,065
Medicare Billing
$318,729
Payment Breakdown by Category
Other$67,660 (55.5%)
Consulting$39,528 (32.4%)
Travel$8,170 (6.7%)
Food & Beverage$3,914 (3.2%)
Research$2,652 (2.2%)
Education$17.77 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $44,885 | 29 | 36.8% |
| Consulting Fee | $39,528 | 15 | 32.4% |
| Honoraria | $22,775 | 10 | 18.7% |
| Travel and Lodging | $8,170 | 27 | 6.7% |
| Food and Beverage | $3,914 | 61 | 3.2% |
| Unspecified | $2,652 | 1 | 2.2% |
| Education | $17.77 | 1 | 0.0% |
Payments by Type
General
$119,289
143 transactions
Research
$2,652
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Deciphera Pharmaceuticals Inc. | $30,033 | 45 | $0 (2024) |
| Daiichi Sankyo Inc. | $27,260 | 24 | $0 (2024) |
| Aadi Bioscience, Inc. | $26,261 | 14 | $0 (2024) |
| Lilly USA, LLC | $15,570 | 25 | $0 (2021) |
| SpringWorks Therapeutics, Inc. | $8,418 | 7 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $3,624 | 2 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $3,227 | 9 | $0 (2018) |
| Eli Lilly and Company | $3,220 | 6 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $2,923 | 2 | $0 (2022) |
| Blueprint Medicines Corporation | $840.00 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $37,861 | 40 | Daiichi Sankyo Inc. ($12,121) |
| 2023 | $35,854 | 40 | Aadi Bioscience, Inc. ($17,642) |
| 2022 | $3,461 | 6 | Deciphera Pharmaceuticals Inc. ($1,750) |
| 2021 | $3,913 | 6 | Deciphera Pharmaceuticals Inc. ($3,846) |
| 2020 | $10,099 | 7 | Daiichi Sankyo Inc. ($9,259) |
| 2019 | $8,513 | 4 | Daiichi Sankyo Inc. ($5,842) |
| 2018 | $10,729 | 26 | Lilly USA, LLC ($7,314) |
| 2017 | $11,512 | 15 | Lilly USA, LLC ($8,210) |
All Payment Transactions
144 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/28/2024 | Daiichi Sankyo Inc. | Turalio (Drug) | Consulting Fee | Cash or cash equivalent | $3,225.00 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Daiichi Sankyo Inc. | Turalio (Drug) | Food and Beverage | In-kind items and services | $78.29 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Daiichi Sankyo Inc. | Turalio (Drug) | Food and Beverage | In-kind items and services | $54.17 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Daiichi Sankyo Inc. | Turalio (Drug) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Consulting Fee | Cash or cash equivalent | $2,775.00 | General |
| Category: ONCOLOGY | ||||||
| 09/17/2024 | Aadi Bioscience, Inc. | Fyarro (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,520.00 | General |
| Category: Cancer | ||||||
| 08/07/2024 | Daiichi Sankyo Inc. | Turalio (Drug) | Consulting Fee | Cash or cash equivalent | $3,547.50 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Honoraria | Cash or cash equivalent | $1,110.00 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Travel and Lodging | In-kind items and services | $655.10 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Travel and Lodging | In-kind items and services | $481.95 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Travel and Lodging | In-kind items and services | $255.46 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $192.50 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $96.60 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $80.50 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $38.50 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2024 | Aadi Bioscience, Inc. | Fyarro (Drug) | Food and Beverage | In-kind items and services | $149.46 | General |
| Category: Cancer | ||||||
| 06/26/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,060.00 | General |
| Category: DESMOID TUMORS | ||||||
| 06/19/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $927.50 | General |
| Category: DESMOID TUMORS | ||||||
| 06/02/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $26.05 | General |
| Category: ONCOLOGY | ||||||
| 05/30/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Honoraria | Cash or cash equivalent | $2,220.00 | General |
| Category: ONCOLOGY | ||||||
| 05/30/2024 | Deciphera Pharmaceuticals Inc. | VIMSELTINIB (Drug) | Food and Beverage | In-kind items and services | $70.80 | General |
| Category: ONCOLOGY | ||||||
| 05/02/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,372.50 | General |
| Category: DESMOID TUMORS | ||||||
| 04/30/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Travel and Lodging | In-kind items and services | $634.40 | General |
| Category: DESMOID TUMORS | ||||||
| 04/18/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Travel and Lodging | In-kind items and services | $312.39 | General |
| Category: DESMOID TUMORS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF DOXORUBICIN PLUS OLARATUMAB VERSUS DOXORUBICIN PLUS PLACEBO IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA | Eli Lilly and Company | $2,652 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 691 | 1,945 | $752,721 | $96,952 |
| 2022 | 14 | 442 | 2,748 | $634,791 | $74,882 |
| 2021 | 14 | 481 | 2,417 | $638,276 | $80,387 |
| 2020 | 15 | 451 | 1,342 | $394,830 | $66,508 |
Total Patients
2,065
Total Services
8,452
Medicare Billing
$318,729
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 117 | 281 | $241,098 | $29,514 | 12.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 64 | 275 | $129,250 | $18,639 | 14.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 47 | 47 | $63,920 | $8,340 | 13.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 76 | $51,680 | $7,754 | 15.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 33 | 48 | $46,080 | $7,329 | 15.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 17 | 48 | $54,464 | $5,691 | 10.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 53 | 57 | $19,090 | $3,923 | 20.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 30 | 33 | $29,370 | $3,676 | 12.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 22 | 22 | $23,870 | $2,973 | 12.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $17,160 | $1,933 | 11.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 83 | 172 | $11,524 | $1,770 | 15.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 22 | $11,176 | $1,655 | 14.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 89 | 188 | $10,904 | $1,423 | 13.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 17 | 97 | $23,765 | $1,329 | 5.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 12 | 33 | $15,675 | $832.67 | 5.3% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 13 | 14 | $630.00 | $82.88 | 13.2% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 21 | 94 | $940.00 | $46.88 | 5.0% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 15 | 425 | $2,125 | $40.80 | 1.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 95 | 275 | $235,950 | $30,152 | 12.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 59 | 106 | $101,760 | $16,607 | 16.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 26 | 86 | $58,480 | $7,479 | 12.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 38 | 38 | $51,680 | $7,025 | 13.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 13 | 47 | $46,906 | $5,684 | 12.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 54 | 180 | $12,060 | $1,884 | 15.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 17 | 119 | $29,155 | $1,767 | 6.1% |
About Dr. Arun Singh, M.D
Dr. Arun Singh, M.D is a Hematology & Oncology healthcare provider based in Santa Monica, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/17/2007. The National Provider Identifier (NPI) number assigned to this provider is 1285817932.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Arun Singh, M.D has received a total of $121,941 in payments from pharmaceutical and medical device companies, with $37,861 received in 2024. These payments were reported across 144 transactions from 15 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($44,885).
As a Medicare-enrolled provider, Singh has provided services to 2,065 Medicare beneficiaries, totaling 8,452 services with total Medicare billing of $318,729. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine
- Location Santa Monica, CA
- Active Since 12/17/2007
- Last Updated 12/14/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1285817932
Products in Payments
- QINLOCK (Drug) $27,742
- Turalio (Drug) $25,325
- Fyarro (Drug) $24,712
- OGSIVEO (Drug) $8,418
- LIBTAYO (Biological) $3,624
- VOTRIENT (Drug) $3,227
- Stivarga (Drug) $2,800
- VIMSELTINIB (Drug) $2,291
- TURALIO (Drug) $1,935
- FYARRO (Drug) $1,550
- AYVAKIT (Drug) $840.00
- CYRAMZA (Drug) $211.87
- ALIYA SYSTEM (Device) $151.60
- Neuwave (Device) $138.25
- Vitrakvi (Drug) $122.88
- TUKYSA (Drug) $62.10
- VERZENIO (Drug) $18.80
- LARTRUVO (Drug) $18.10
- LORBRENA (Drug) $17.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Santa Monica
Omid Hamid, M.d, M.D
Hematology & Oncology — Payments: $981,950
Hematology & Oncology $981,950
Steven O'day, M.d, M.D
Hematology & Oncology — Payments: $594,773
Hematology & Oncology $594,773
Steven Wong, Md, MD
Hematology & Oncology — Payments: $421,118
Hematology & Oncology $421,118
Silvana Martino, D.o, D.O
Hematology & Oncology — Payments: $179,144
Hematology & Oncology $179,144
Miss. Blanca Ledezma, Msn, Np, MSN, NP
Hematology & Oncology — Payments: $148,836
Hematology & Oncology $148,836
Dr. William Isacoff, M.d, M.D
Hematology & Oncology — Payments: $108,579
Hematology & Oncology $108,579